<DOC>
	<DOCNO>NCT02950922</DOCNO>
	<brief_summary>This multi-center , randomize , vehicle-controlled , double-blind Phase 2 study adult adolescent subject mild moderate atopic dermatitis .</brief_summary>
	<brief_title>Study RVT-501 Adult Adolescent Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>The purpose study evaluate safety , efficacy , pharmacokinetics 0.2 % BID 0.5 % concentration RVT-501 patient atopic dermatitis .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Males female confirm diagnosis atopic dermatitis Hanifin Rajka criterion ( Appendix 4 : Criteria Atopic Dermatitis Diagnosis ) . For adult subject , age range 18 70 year . For adolescent subject , age range 12 17 year . 2 . Subjects atopic dermatitis cover ≥ 3 % &lt; 40 % body surface area Investigator Global Assessment ( IGA ) 2 3 ( mild moderate ) baseline . Scalp , palm sol exclude BSA calculation determine eligibility baseline . NOTE : Subjects mild disease ( IGA =2 ) limit approximately 25 % total enrollment . 3 . Minimum EASI score 7 baseline . 4 . Females childbearing potential male subject engage sexual activity could lead pregnancy must use follow adequate birth control method study 2 week stop study drug . Acceptable contraception method : Male Male partner vasectomy OR Male condom , AND partner use one contraceptive option : Spermicide Contraceptive subdermal implant meet effectiveness criterion include &lt; 1 % rate failure per year , state product label Intrauterine device intrauterine system meet effectiveness criterion include &lt; 1 % rate failure per year , state product label [ Hatcher , 2007a ] Oral Contraceptive , either combined progestogen alone [ Hatcher , 2007a ] Injectable progestogen [ Hatcher , 2007a ] Contraceptive vaginal ring [ Hatcher , 2007a ] Percutaneous contraceptive patch [ Hatcher , 2007a ] These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Nonchildbearing potential define premenopausal female document bilateral tubal ligation , bilateral oophorectomy ( removal ovary ) hysterectomy ; hysteroscopic sterilization ; postmenopausal define 12 month spontaneous amenorrhea . In questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40mlU confirmatory . Documented verbal history subject acceptable . 5 . Atopic Dermatitis present least 12 month accord patient/care giver stable disease least 1 month accord patient/care giver . 6 . Capable give write informed consent , include compliance requirement restriction list consent form . A subject eligible inclusion study follow criterion apply : 1 . A positive Hepatitis B surface antigen positive Hepatitis C antibody result screen . 2 . A positive test human immunodeficiency virus ( HIV ) antibody screen . 3 . Screening alanine aminotransferase ( ALT ) ≥ 3x upper limit normal ( ULN ) . 4 . Total bilirubin &gt; 1.5x upper limit normal ( ULN ) ; total bilirubin &gt; ULN ≤ 1.5x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % . 5 . Corrected QT ( QTc ) interval &gt; 475 msec &gt; 525 msec presence bundle branch block . 6 . Subjects present illness Kaposi 's varicelliform eruption , scabies , molluscum contagiosum , impetigo , psoriasis , connective tissue disorder , Netherton 's syndrome , disease could effect pathological evaluation atopic dermatitis . 7 . Use prohibit medication . Prohibited concomitant medication , therapy , etc . defined period follow . If subject require medication throughout study period , he/she may exclude discontinue study , discretion investigator medical monitor . From 6 month prior first application study drug completion followup examination discontinuation : Biological product might significantly affect evaluation atopic dermatitis condition ( e.g. , TNF inhibitor , antiIgE antibody , antiCD20 antibody , antiIL4 receptor ) From 28 day prior first application study drug completion Treatment Phase discontinuation : Corticosteroid preparation ( oral , injection , suppository preparation ) topical corticosteroid classify super high potency ( clobetasol propionate ) . Eye drop nasal preparation allow . Inhaled preparation allow use stable condition stable dose &gt; 28 day screening , continue dose throughout study . Oral preparation injection immunosuppressant ( cyclosporine , methotrexate , azathioprine , tacrolimus , etc . ) Over counter herbal medicine atopic dermatitis ( topical oral preparation ) Excessive sun exposure , tan booth , UV light source phototherapy include PUVA therapy From 7 day prior first application study drug completion Treatment Phase discontinuation : Topical corticosteroid classify low , medium , high potency ( fluocinonide , triamcinolone acetonide , desonide , hydrocortisone ) . Eye drop nasal preparation allow . Tacrolimus pimecrolimus cream and/or ointment Antihistamines/antiallergics ( oral , topical injection ) : diphenhydramine , chlorpheniramine maleate , hydroxyzine ) . NOTE : The follow antihistamine allow : Loratadine , fexofenadine hydrochloride , cetirizine hydrochloride From baseline throughout treatment period 8 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 9 . Pregnant female determine positive serum ( screen ) urine ( baseline ) human chorionic gonadotropin test screen prior dosing . 10 . Lactating female . 11 . History sensitivity study medication , component thereof history drug allergy , opinion Investigator Medical Monitor , contraindicate participation . 12 . The subject receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 13 . Current history cancer within 5 year exception fully excise skin basal cell carcinoma , squamous cell carcinoma carcinoma situ cervix . 14 . Subjects active infection require oral intravenous administration antibiotic , antifungal antiviral agent within 7 day Baseline/Day 0 . 15 . Concurrent skin lesion treatment area pruritus due condition atopic dermatitis , opinion investigator , would either interfere study evaluation affect safety subject . 16 . Subjects advance disease abnormal laboratory test value could affect safety subject implementation study . 17 . Evidence significant hepatic , renal , respiratory , endocrine , hematologic , neurologic , psychiatric , cardiovascular system abnormality laboratory abnormality affect health subject interfere interpretation result . 18 . The subject excessive sun exposure , plan trip sunny climate would involve excessive sun exposure , use tan booth within 28 day prior baseline ( Day 0 ) willing minimize natural artificial sunlight exposure study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>